Is Viatris' Shift Into Complex Therapies Altering The Investment Case For VTRS? [Yahoo! Finance]
Viatris Inc. (VTRS)
Company Research
Source: Yahoo! Finance
progress on a low-dose contraceptive patch, an ophthalmology candidate for neurotrophic keratopathy, and pitolisant for obstructive sleep apnea in Japan. These advances highlight Viatris' push into complex injectables, transdermal contraception, and specialty treatments, broadening its portfolio beyond traditional, lower-margin generics. Next, we'll examine how the FDA approval of octreotide acetate and other pipeline advances may reshape Viatris' existing investment narrative. Find companies with promising cash flow potential yet trading below their fair value To own Viatris, you need to believe it can turn a mature, price-pressured generics base into a steadier, higher-value business while managing its debt load. The latest pipeline milestones support that shift toward complex and specialty products, but they do not fundamentally change the near term focus on stabilizing margins and improving operational efficiency, nor the key risk that price erosion and competition in core
Show less
Read more
Impact Snapshot
Event Time:
VTRS
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VTRS alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VTRS alerts
High impacting Viatris Inc. news events
Weekly update
A roundup of the hottest topics
VTRS
News
- Why Viatris (VTRS) Stock Is Up Today [Yahoo! Finance]Yahoo! Finance
- A Look At Viatris (VTRS) Valuation After The New Chief Legal Officer Appointment [Yahoo! Finance]Yahoo! Finance
- Viatris to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026, and Host Investor Event on March 19, 2026PR Newswire
- Mapi Pharma to Present New Safety and Efficacy Data from Glatiramer Acetate Depot Long-Acting Injection Phase II Study in Patients with Primary Progressive Multiple Sclerosis (PPMS) at ACTRIMS Forum 2026 [Yahoo! Finance]Yahoo! Finance
- Viatris Appoints Matthew J. Maletta as Chief Legal Officer [Yahoo! Finance]Yahoo! Finance
VTRS
Earnings
- 11/6/25 - Beat
VTRS
Sec Filings
- 2/4/26 - Form SCHEDULE
- 2/3/26 - Form 8-K
- 1/2/26 - Form 4
- VTRS's page on the SEC website